Exciting Announcement from IVY Growth Associates Associates!
IVY Growth Associates, a prominent micro venture capital firm, proudly announces the launch of Arigato Capital, a SEBI-registered Category I AIF VC fund. With a target corpus of Rs 250 crore, this sector-agnostic fund is set to invest in startups across diverse emerging sectors such as agritech, cleantech, generative AI, fintech, consumer brands, and SaaS.
Arigato Capital will commence capital raising in June 2024, aiming to close all commitments within 15 to 18 months. The fund targets a first close at Rs 100 crore and will focus on startups beyond the seed stage or in pre-Series A stages, with an average ticket size of $500,000.
Founded by Prateek Tosniwal , Rachit Poddar, Mehul Shah, and Sharad Todi, Arigato Capital has IVY Growth Associates as a limited partner. The fund aims to create a global corridor connecting angel investors and startups, especially in the Middle East, the US, and Europe.
In addition to launching Arigato Capital, IVY Growth Associates will host the third edition of its startup summit, 21BY72, from June 15 to June 16 in Surat. The summit is expected to attract over 20,000 participants, including more than 200 startup founders, 200 venture capitalists, and over 500 investors.
With a strong track record, IVY Growth Associates has invested in over 100 growth-stage startups, deploying Rs 20 crore from its fund and over Rs 80 crore from syndicate funds within its network. Notable portfolio brands include Rupeek, BluSmart, and Zappfresh.
In October 2023, IVY Growth announced plans to launch IVY Growth Fund, a $30 million VC fund targeting revenue-based and traction-based startups, set to begin in FY25.
#IVYGrowthAssociates #ArigatoCapital #VentureCapital #StartupFunding #Innovation #Investment #Startups #21BY72 #SEBI #VCfund #EmergingSectors
https://lnkd.in/gBiXnjCC
Great insight, Bruce. Have you considered leveraging predictive analytics to identify emerging trends, diversifying investment strategies to embrace not just biotech but the intersection of tech and healthcare for robust portfolio growth?